libre de droit/iStock via Getty Images Inventiva (NASDAQ:IVA) stock rose 10% in after-hours trading Friday after the French biotech company said it was working towards securing a royalty-based financing deal that would extend its cash runway through the summer. The company said in a statement that it had cash andContinue Reading
A new study has linked the use of GLP-1 drugs and metformin to a lower risk of developing certain obesity-related cancers in patients with Type 2 diabetes. The study, which was published Friday on the JAMA Network Open website, showed that patients taking GLP-1 drugs or metformin showed a significantlyContinue Reading
A recent study by UC Berkeley Public Health that indicates levels of toxic chemicals in tampons could have implications for Kimberly-Clark Corporation (NYSE:KMB), Edgewell (NYSE:EPC), and Proctor & Gamble (NYSE:PG) as the major manufacturers of feminine hygiene products. Although varied by where the tampons were manufactured (US vs the EUContinue Reading
Carl Lokko Alvotech (NASDAQ:ALVO) said a confirmatory study for its biosimilar candidate AVT03 met its primary endpoint of demonstrating clinical similarity to Amgen’s (AMGN) osteoporosis drug Prolia. The Icelandic company said the study demonstrated similarity of AVT03 to Prolia, also known as denosumab, in terms of efficacy, safety, immunogenicity andContinue Reading
As a leader in the athletic sportswear category, Nike’s (NYSE:NKE) quarterly results not only bring an unofficial close to earnings season but are viewed as a barometer to consumer spending trends and the company’s success penetrating foreign markets. Wall Street will dissect FQ4 results next week for not only theContinue Reading
Devonyu A new peer-reviewed study suggested this week that GLP-1 drugs, popularly used for weight loss, are associated with a lower risk of dementia in older people with diabetes. The trial considered real-world data from Sweden using more than 88,000 patients aged 65 or older with type 2 diabetes mellitusContinue Reading
duoogle Baird said it believes the recent Phase 2 study failure for Jazz Pharmaceuticals’ (JAZZ) drug suvecaltamide has favorable readthrough to Praxis Precision Medicines’ (NASDAQ:PRAX) drug ulixacaltamide in the treatment of essential tremor. The investment firm said Jazz’s data has minimal impact on the probability of success for Praxis’s PhaseContinue Reading
